AU2018236352B2 - Methods and compositions for inducing immune responses against clostridium difficile - Google Patents

Methods and compositions for inducing immune responses against clostridium difficile Download PDF

Info

Publication number
AU2018236352B2
AU2018236352B2 AU2018236352A AU2018236352A AU2018236352B2 AU 2018236352 B2 AU2018236352 B2 AU 2018236352B2 AU 2018236352 A AU2018236352 A AU 2018236352A AU 2018236352 A AU2018236352 A AU 2018236352A AU 2018236352 B2 AU2018236352 B2 AU 2018236352B2
Authority
AU
Australia
Prior art keywords
asn
ile
gly
asp
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018236352A
Other languages
English (en)
Other versions
AU2018236352A1 (en
Inventor
David Flyer
Gregory Glenn
Ye Liu
Gale Smith
Jing-Hui Tian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novavax Inc
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of AU2018236352A1 publication Critical patent/AU2018236352A1/en
Application granted granted Critical
Publication of AU2018236352B2 publication Critical patent/AU2018236352B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2018236352A 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile Active AU2018236352B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762471636P 2017-03-15 2017-03-15
US62/471,636 2017-03-15
US201762474434P 2017-03-21 2017-03-21
US62/474,434 2017-03-21
PCT/US2018/022597 WO2018170238A2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Publications (2)

Publication Number Publication Date
AU2018236352A1 AU2018236352A1 (en) 2019-10-03
AU2018236352B2 true AU2018236352B2 (en) 2024-04-04

Family

ID=63523217

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018236352A Active AU2018236352B2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Country Status (12)

Country Link
US (2) US11123419B2 (cg-RX-API-DMAC7.html)
EP (1) EP3595709A4 (cg-RX-API-DMAC7.html)
JP (2) JP7149285B2 (cg-RX-API-DMAC7.html)
KR (1) KR102640722B1 (cg-RX-API-DMAC7.html)
CN (1) CN110691609B (cg-RX-API-DMAC7.html)
AU (1) AU2018236352B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019019117A2 (cg-RX-API-DMAC7.html)
CA (1) CA3056090A1 (cg-RX-API-DMAC7.html)
IL (1) IL269258B2 (cg-RX-API-DMAC7.html)
MX (1) MX2019010948A (cg-RX-API-DMAC7.html)
SG (1) SG11201908376UA (cg-RX-API-DMAC7.html)
WO (1) WO2018170238A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013027229B1 (pt) 2011-04-22 2020-10-27 Wyeth Llc polipeptídeo imunogênico isolado e seu uso, composição imunogênica e seu uso, célula recombinante ou progênie da mesma, e método de produção de uma toxina de clostridium difficile mutante
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
US20230218735A1 (en) * 2020-06-19 2023-07-13 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112867A1 (en) * 2012-01-27 2013-08-01 Merck Sharp & Dohme Corp. Vaccines against clostridium difficile comprising recombinant toxins

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
WO1999011711A1 (en) * 1997-09-04 1999-03-11 Eastman Chemical Company Thermoplastic polyurethane additives for enhancing solid state polymerization rates
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20130039973A1 (en) 2011-08-03 2013-02-14 Henry J. Smith Viral Immunogenic Compositions
SG11201400999VA (en) * 2011-09-30 2014-07-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
CN112807422A (zh) * 2012-12-05 2021-05-18 葛兰素史密丝克莱恩生物有限公司 免疫原性组合物
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
EP2988778A4 (en) * 2013-04-22 2016-12-14 Board Of Regents Of The Univ Of Oklahoma CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE
MX2016005656A (es) * 2013-11-01 2016-07-14 Pfizer Vectores para expresion de antigenos asociados a prostata.
PL3160500T3 (pl) * 2014-06-25 2020-02-28 Glaxosmithkline Biologicals S.A. Immunogenna kompozycja clostridium difficile
CN106220737B (zh) * 2016-07-21 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 融合蛋白及其在治疗艰难梭菌相关疾病中的应用
CA3056090A1 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013112867A1 (en) * 2012-01-27 2013-08-01 Merck Sharp & Dohme Corp. Vaccines against clostridium difficile comprising recombinant toxins

Also Published As

Publication number Publication date
IL269258A (en) 2019-11-28
KR20190125470A (ko) 2019-11-06
AU2018236352A1 (en) 2019-10-03
US11123419B2 (en) 2021-09-21
IL269258B2 (en) 2023-09-01
JP2022179543A (ja) 2022-12-02
US20220211834A1 (en) 2022-07-07
SG11201908376UA (en) 2019-10-30
MX2019010948A (es) 2020-01-09
JP7397145B2 (ja) 2023-12-12
CN110691609A (zh) 2020-01-14
RU2019132111A (ru) 2021-04-15
JP2020509770A (ja) 2020-04-02
IL269258B1 (en) 2023-05-01
WO2018170238A3 (en) 2018-10-18
EP3595709A4 (en) 2020-12-23
EP3595709A2 (en) 2020-01-22
CN110691609B (zh) 2024-04-19
WO2018170238A2 (en) 2018-09-20
JP7149285B2 (ja) 2022-10-06
BR112019019117A2 (pt) 2020-05-05
US11938179B2 (en) 2024-03-26
CA3056090A1 (en) 2018-09-20
KR102640722B1 (ko) 2024-02-26
US20200085934A1 (en) 2020-03-19
RU2019132111A3 (cg-RX-API-DMAC7.html) 2021-06-29

Similar Documents

Publication Publication Date Title
US11938179B2 (en) Methods and compositions for inducing immune responses against Clostridium difficile
JP6351641B2 (ja) ノロウイルスに由来する免疫原性組成物および方法
CA2774640C (en) Virus like particles comprising target proteins fused to plant viral coat proteins
EP2061887B1 (en) Vlp based influenza vaccine delivery system
EP3344291A2 (en) Vaccine compositions having improved stability and immunogenicity
CN107056901A (zh) 脑膜炎双球菌组合物及其方法
US20020119529A1 (en) Enhancement of b cell activation and immunoglobulin secretion by co-stimulation of receptors for antigen and ebv gp350/220
KR20140101835A (ko) 클로스트리듐 디피실레 톡신-기반 백신
JP2012532626A (ja) 無毒化されたＥｓｃｈｅｒｉｃｈｉａｃｏｌｉ免疫原
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
CN104560780B (zh) 产气荚膜梭菌ε毒素减毒突变体及其应用
WO2022040220A2 (en) Severe acute respiratory syndrome coronavirus [sars-cov-2]-virus-like particle [vlp] vaccine: compositions, delivery strategies, methods and uses
JPH05509226A (ja) Ｅｈｖ―４糖蛋白質ワクチン
WO2017113050A1 (zh) 猪圆环病毒2型的外鞘蛋白质的制备方法及含该外鞘蛋白质的医药组合物
RU2781057C2 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
RU2781057C9 (ru) Способы и композиции для индукции иммунного ответа против clostridium difficile
CN117003885B (zh) H5n8禽流感广谱性疫苗的开发及其应用
US9493518B2 (en) Compositions and methods for treating clostridium difficile-associated diseases
CA3131551A1 (en) Methods for preventing disease or disorder caused by rsv infection
US20240335523A1 (en) Glycoengineered Foldon Domains and Related Compositions and Methods
CN116940372A (zh) 流感嗜血杆菌疫苗和使用方法
TW201722983A (zh) 豬第二型環狀病毒之外鞘蛋白質的製備方法及含該外鞘蛋白質的醫藥組合物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)